This is a non-core endpoint: only basic statistics are computed.
Linear scleroderma
DOID EFO MESH Endpoint Browser
L12_LINEARSCLERODERMA
scleroderma: Scleroderma is a rare autoimmune connective tissue disorder characterized by abnormal hardening of the skin and, sometimes, other organs. It is classified into two main forms: localized scleroderma and systemic sclerosis (SSc), the latter comprising three subsets; diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc) and limited SSc (lSSc) (see these terms).
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
30
Check minimum number of events None
30
Include endpoints None
30
Remove individuals based on genotype QC
29
L12_LINEARSCLERODERMA
Control definitions
Control exclude
L12_OTHERSKINSUBCUTIS
Extra metadata
Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
L94
Name in latin
Scleroderma lineare
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Linear scleroderma
based on the number of shared cases.
Broader endpoints:
- Other localized connective tissue disorders
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 29 | 22 | 7 |
| Unadjusted prevalence (%) | 0.01 | 0.01 | 0.00 |
| Mean age at first event (years) | 38.88 | 37.09 | 44.52 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: L12_LINEARSCLERODERMA – Linear scleroderma
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Linear scleroderma
↥Endpoint not on priority list, no data to show.